- About us
- Join Putnam
We worked with our client to develop a forward-looking early development program evaluation tool that identifies key inflection points, value drivers and risks for the client’s early oncology portfolio. (US was the geographic scope).
We delivered on a commercial analysis of the portfolio with regards to relative potential of the programs along with their key value drivers, milestones, risks and gaps over a 10-year time horizon for key stakeholders.
Putnam PHMR’s client needed a detailed description of multiple myeloma treatment patterns and resource utilization in Japanese patients...
An emerging biotech sought Putnam’s guidance to design and execute the global commercialization of their asset for a rare oncology indication.
A global, top-10 pharma client sought Putnam’s guidance on developing a lean launch strategy for a novel cell therapy in oncology.